CARDIONATE IN COMBINED THERAPY OF ISCHEMIC CHRONIC HEART FAILURE AMONG PATIENTS WITH METABOLIC SYNDROME
This 12-week study included 60 patients (age 45-65 years) with metabolic syndrome (MS), chronic heart failure (CHF) of II-III functional class (FC), and recent myocardial infarction. The participants were randomised into two groups (n=30 for each). In the main group, standard CHF therapy was combine...
Main Authors: | M. E. Statsenko, S. V. Turkina, E. D. Evtereva, O. E. Sporova, S. V. Fabritskaya |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2010-08-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1466 |
Similar Items
-
MEXICOR EFFECTIVENESS IN PATIENTS WITH CHRONIC HEART FAILURE AND METABOLIC SYNDROME
by: M. E. Statsenko, et al.
Published: (2009-12-01) -
NEW POTENTIAL OF MEXICOR IN THE TREATMENT OF CHRONIC HEART FAILURE AMONG PATIENTS WITH METABOLIC SYNDROME
by: M. E. Statsenko, et al.
Published: (2010-12-01) -
EFFECTS OF MILDRONATE, AS A PART OF COMBINED HEART FAILURE THERAPY, ON CARBOHYDRATE AND LIPID METABOLISM AND OXIDATIVE STRESS PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: M. E. Statsenko, et al.
Published: (2010-04-01) -
Endothelium protecting properties of taurin in chronic heart failure with type 2 diabetes
by: M. E. Stacenko, et al.
Published: (2016-04-01) -
Carbohydrate metabolism disorders in patients with heart failure: data from the local registry
by: A. R. Vaisberg, et al.
Published: (2021-04-01)